United Kingdom (UK)
Recombinant monoclonal antibody to IGF-IR. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 7C10.
UniProt Accession Number of Target Protein: P08069
Alternative Name(s) of Target: Insulin-like growth factor 1 receptor; IGF1R; Insulin-like growth factor I receptor; IGF-I receptor; CD221
Immunogen: The original mouse antibody was raised by immunizing mice with recombinant human IGF-IR.
Specificity: The antibody is specific for human IGF-IR. It does not prevent clone 12BI from binding to the same protein. IGF-IR is a receptor tyrosine kinase which mediates actions of insulin-like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and insulin (INS) with a lower affinity. The activated IGF1R is involved in cell growth and survival control.
Application Notes: Specificity of this antibody was confirmed by ELISA (WO2009017679). Further, western blot was preformed to test whether the antibody cross reacts with IR protein (WO2009017679). It was also observed that the human version of this antibody was useful for antibody dependent cell cytotoxicity assays; MCF-7 or A549 target cells were incubated with this antibody and human natural killer cells. It was shown that the antibody does increase lysis of these cells (Goetsch et al, 2005; pmid:15386423). Furthermore, it was shown that the human version of this antibody is able to inhibit growth of MDA-MB-231, an oestrogen-independent breast cancer cell line in mice (Pandini et al, 2007; pmid:17451939). The human version of this antibody was also used in immunofluorescence on MCF-7 cells (Broussas et al, 2009; pmid:19165858). Finally, human version of this antibody was utilized in western blot of MCF-7 cells tumors (Broussas et al, 2009; pmid:19165858).
Antibody first published in:
Goetsch et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts Int J Cancer. 2005 Jan 10;113(2):316-28. PMID:15386423
Note on publication:
Describes the generation of a humanized anti-IGF-IR antibody h7C10 that blocks in vitro IGF-I and IGF-II-induced cell proliferation of MCF-7 breast cancer cells.